Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With Cardiovascular Disease (CVD) and Elevated Lp(a)
Study context
- Population
- Patients with established CVD (history of myocardial infarction (MI), ischemic stroke or symptomatic peripheral artery disease) and elevated Lp(a) levels of ≥70 mg/dL (≈149 nmol/L)patients randomized
- Participants
- 8,323 patients
- Planned comparison
- Pelacarsen 80 mg monthly vs matching placebo
- Primary endpoint
- Composite of cardiovascular death, nonfatal MI, nonfatal stroke, or urgent coronary revascularization requiring hospitalization; evaluated in the overall population and in a subpopulation of Lp(a) ≥90 mg/dL (≈192 nmol/L) at screening
Methodological detailsdesign and rationale (no results reported), event-driven: study ends when 993 CEC confirmed primary CV events have accumulated, minimum follow-up 2.5 years, 1:1 randomization
- Design and rationale (no results reported)
- Event-driven: study ends when 993 CEC confirmed primary CV events have accumulated
- Minimum follow-up 2.5 years
- 1:1 randomization
No results yet. This paper sets out the design of a trial; its results are to come.
Further findings
- Overall study duration anticipated, based on the current event accrual trend
- ≈6 years
Original publication
Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a). Am Heart J. Published 2 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →